News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes! $BON (@$.42) = $$$$$$$! Market Cap: $4.68M ~ Shares in Issue: 11.15 ~ Float: 7.13M ~ Revenue: $29.91M ~ (Net)Profit/Loss: $6.24M(!) ~ EPS: 0.56(!) ~ PE Ratio: 0.75(!) ~ % Held by Insiders: 43.03%(!) ~ % Held by Institutions: 0.97% ~ Book Value Per Share (mrq): $3.14(!) ~ Projected Stock Price: $7.90(!) (+1,787.99%(!)) (Estimated share price by October 5, 2024) >>> https://fintel.io/sfo/us/bon <<<
$$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$
$$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$ $$$BON$$$
Newest (3rd) production facility Yumen Plant going to boost #s together with latest 'deal' (MOU) with Guangdong Jiangwang International Holdings Limited (“Jiangwang”). This MOU allows the parties to negotiate the terms and conditions of a definitive agreement for $BON to distribute Jiangwang’s Chinese White Spirits (“Spirits”) and other related health products in China Markets. >>> News pending imo. $BON $$$$$$$
$BON >>> AMERICAN BULLS: STAY LONG! 'Uptrend is in progress' $$$$$$$
Link: https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=BON
$$$BON$$$
$BON ~ LT-Chart (Big Picture) $$$$$$$ >LOADING-ZONE< $$$$$$$
$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$
$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$$$$BON$$$
$BON ~ Bon Natural Life Ltd
@0.5001 (AH) > +0.0314 (+6.70%)
Volume: 641,191(!)
Day Range: 0.4473 - 0.589(!)
Last Trade Time: 7:29:37 PM EDT
Bid Price: 0.5002
Ask Price: 0.5418
$$$BON$$$
$BON >>> Bon Natural Life (BON) Regains Nasdaq Compliance
Corporate News (October 12, 2023 12:58 PM EDT)
On June 30, 2023, Bon Natural Life (NASDAQ: BON) received a letter from Nasdaq Stock Market, LLC, notifying the Company that it no longer complied with Nasdaq’s majority independent board and independent audit, compensation, and nominating committee requirements as set forth in Listing Rule 5605. As disclosed in its Report on Form 6-K filed with the SEC on August 4, 2023, the Company appointed Jianjun Gao, Ph.D. as a new independent director on August 2, 2023. As disclosed in its Report on Form 6-K filed with the SEC on October 5, 2023, the Company appointed Jing Chen and Zhixiang Gao as additional independent directors on October 2, 2023.
On October 9, 2023, the Company received notification from Nasdaq that it has regained compliance with Listing Rule 5605.
https://www.streetinsider.com/Corporate+News/Bon+Natural+Life+%28BON%29+Regains+Nasdaq+Compliance/22267069.html
BON new 52 week low
|
Followers
|
1
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14
|
|
Created
|
08/22/22
|
Type
|
Free
|
| Moderators | |||
September 11, 2023 11:37 ET| Source: Bon Natural Life Limited
XI’AN, China, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its half-year financial results for the six months ended March 31, 2023.
1H-2023 Financial Highlights
1H-2023 Product Categories Summary: Growth vs. Prior Year
| Revenues increase (decrease) | Gross Profits increase (decrease) | |
| Fragrance Compounds | (8.4%) | 12.3% |
| Health Supplements (Powder Drinks) | 37.2% | 21.0% |
| Bioactive Food Ingredients | (5.2%) | 20.0% |
Fragrance Compounds
Revenues from sales of fragrance compound products decreased by 8.4% to US$6.8 million in the six months ended March 31, 2023 from US$7.4 million for the same period in 2022. The decrease was primarily attributable to a 10.1% decrease in average selling price and a 9.5% negative impact from currency exchange, partially offset by an increase of 1.8% in sales volume.
Gross profit from fragrance compound products increased by 12.3% to US$2.0 million from US$1.8 million for the same period in 2022. The increase was primarily attributable to a 16.6% decrease in cost of products due to our ability to negotiate better price from suppliers and an increase of 1.8% in sales volume, partially offset by a 9.5% negative impact from currency exchange.
Health Supplements (Powder Drinks)
Revenues from sales of health supplement (powder drinks) products increased by 37.2% to US$4.6 million in the six months ended March 31, 2023 from US$3.3 million for the same period in 2022. The increase was primarily attributable to an increase of 50% in sales volume and partially offset by a 9.5% negative impact from currency exchange.
Gross profit from health supplement (powder drinks) products increased by 21.0% to US$1.4 million from US$1.2 million for the same period in 2022. The increase was primarily attributable to the above referenced factors.
Bioactive Food Ingredients
Revenues from sales of bioactive food ingredient products decreased by 5.2% to US$2.8 million in the six months ended March 31, 2023 from US$2.9 million for the same period in 2022. The decrease was primarily attributable to a 7.5% decrease in average price and a 9.5% negative impact from currency exchange, partially offset by a 2.4% increase in sales volume due to strong customer demand and sales effort.
Gross profit from bioactive food ingredient products increased by 20.0% to US$1.3 million from US$1.1 million for the same period in 2022. The increase was mainly due to a 2.4% increase in sales volume and a decrease of 21.7% in cost of products due to the decreased raw materials purchase price, partially offset by a 9.5% negative impact from currency exchange.
General and administrative expenses increased by $467,012, or approximately 46.8%, from $998,943 in the six months ended March 31, 2022, to $1,465,955 in the same period of 2023, mainly attributable to an increase of 44.2% in staff payroll due to the increase in staff headcount, a 234.8% increase in rent expenses and a 42.7% increase in expenses such as professional service and consulting fees and investor relation expenses, etc. as we become a public company since we completed the IPO in July 2021.
Research and development (“R&D”) expenses decreased by $34,680, or approximately 21.1%, from $164,675 in the six months ended March 31, 2022, to $129,995 in the same period of 2023. The decrease was mainly due to a 79.3% decrease in staff payroll and a 34.4% decrease in outsourcing R&D activities to external consulting firms.
Government subsidies received in the form of provincial-level export credit insurance subsidy and unemployment insurance expansion grant totaled $11,916 in the six months ended March 31, 2023.
Net income decreased from $2.5 million in the six months ended March 31, 2022 to $2.1 million in the same period of 2023.
Net cash used in operating activities during the six months ended March 31, 2023 was $2,177,992 compared to net cash used in operating activities of $130,577 in the same period of 2022.
Diluted earnings per share ("EPS") was $0.24, compared to $0.30 for the same period in 2022.
Investors are encouraged to review the Company’s complete financial statements and related disclosures for additional information. These materials are available at https://www.sec.gov/edgar/browse/?CIK=1816815&owner=exclude
About Bon Natural Life Limited
The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.
February 10, 2023 08:30 ET| Source: Bon Natural Life Limited
Revenue increased by 17.3% to $29.9 million.
Xian, China, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its 2022 annual financial results for the fiscal year ended September 30, 2022.
FY 2022 Financial Highlights
Management Commentary
“We are pleased to conclude fiscal 2022 with solid growth in both top and bottom lines compared to fiscal year 2021 despite challenges caused by volatile global environment including high inflation, supply chain disruption, and persistent outbreak of COVID-19 pandemic in last year.” Commented Richard (Yongwei) Hu, BON’s Chairman & CEO, “I would like to recognize our team for their contribution in navigating through these conditions by market strategy adjustment, disciplined cost management as well as pricing efforts. Thanks to their relentless effort and hard work, the gross profits of fragrance compound, health supplemental powder drinks and bioactive food ingredients increased by 27.3%, 10.4% and 61.4% from the prior year. Our net income grew 35.4% to $6.2 million.”
“Looking ahead to 2023, we expect the first-phase completion of our third production site - Yumen Plant in May 2023. Once up and running, Yumen Plant will add 150% revenue growth potential on an annualized basis. In addition, the successful launch of our new vegetable based probiotic powder drink for regulation and improvement of human's overall microbiome and digestive health, as well as natural based personal care product for female hygiene health will attract more natural health-conscious consumers and further drive revenue growth for BON. Last but not the least, the reopening of China will help boost our profit by alleviate pressures from supply chain and logistics. With our new Yumen plant, our new natural based products, along with post-COVID reopening, we are confident to deliver the sustainable growth and create lasting long-term value for our shareholders.”
FY 2022 Product Categories Summary: Growth vs. Prior Year
| Revenues increase | Gross Profits increase | |||
| Fragrance Compounds | 7.6 | % | 27.3 | % |
| Health Supplements (Powder Drinks) | 7.4 | % | 10.4 | % |
| Bioactive Food Ingredients | 48.5 | % | 61.4 | % |
Fragrance Compounds
Health Supplements (Powder Drinks)
Bioactive Food Ingredients
Selling expenses increased by $80,292, or approximately 58.0%, from $138,530 to $218,822 in the same period of 2021, mainly attributable to increase of advertising expense, salaries and social benefits on attending more trade shows as well as recruiting more sales staff.
Research and development (“R&D”) expenses increased by $175,508, or approximately 70.5%, from $249,050 in fiscal year 2021 to $424,558 in fiscal year 2022. The increase was mainly due to an increase of $140,504 in outsourcing R&D activities to external consulting firms.
Government subsidies received in the form of a grant and recognized as other operating income totaled $1,306,627 and $449,972 for the fiscal years ended September 30, 2022 and 2021, respectively.
Net income increased from $4.6 million in the fiscal year ended September 30, 2021 to $6.2 million in the same period of 2022.
Net cash used in operating activities during the year ended September 30, 2022 was $0.2 million compared to $4.1 million net cash provided by operating activities in the same period of 2021. The decrease was mainly attribute to a decrease of $3,632,922 in taxes payable primarily due to income and VAT tax paid in fiscal year 2022, an increase of $1,300,942 account receivable due to increased sales in the year ended September 30, 2022, and decrease in deferred revenue of $875,295 due to changes in customer payment pattern related with COVID-19.
Basic earnings per share (“EPS”) was $0.75, compared to $0.69 for the same period in 2021.
Diluted earnings per share (“EPS”) was $0.74, compared to $0.68 for the same period in 2021.
Subsequent Events
Investor Conference Call and Webcast
A live webcast to discuss the Company’s FY 2022 financial results will be held on February 10, 2023, beginning at 9:00 a.m. EST. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at https://www.bnlus.com/investorrelations-ep. The webcast also can be accessed by using the direct link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=oKNXFTV5 . For those unable to listen to the live webcast, a recorded version will be available on the Company’s website after the event.
Pre-registration: https://dpregister.com/sreg/10175699/f5ecaa11e8
Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the operator. Participants may pre-register at any time, up to and including after the time that the call has started.
Those without internet access or unable to pre-register may dial in by calling:
U.S. Toll Free: 1-866-777-2509 | International Toll: 1-412-317-5413
About Bon Natural Life Limited
The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.
